











Emilia, ModenNeural Damage Biomarkers during Open
Carotid Surgery versus Endovascular
Approach*Enrico Giuliani,1 Susanna Genedani,2 Roberto Moratto,3 Jessica Veronesi,3 Chiara Carone,2
Cinzia Bonvecchio,1 Francesco Mosca,1 Gioachino Coppi,3 and Alberto Barbieri,1 Modena, ItalyBackground: Carotid endarterectomy (CEA) is the gold standard for treating severe carotid ar-
tery stenosis, whereas carotid artery stenting (CAS) represents an endovascular alternative. The
objective of this study was to assess the potential neural damage following open or endovascu-
lar carotid surgery measured by peripheral blood concentration of 3 biomarkers: S100b, matrix
metalloproteinase-9 (MMP-9), and D-dimer.
Methods: Data for this prospective investigation were obtained from the Carotid Markers study
(January 2010e2011), which sought to measure the levels of specific biomarkers of neuronal
damage and thrombosis on candidates to CEA or CAS presenting at the Department of Vascular
Surgery of the Nuovo Ospedale S. Agostino Estense of Modena (Italy) at baseline and at 24 hr
after surgery. Relevant medical comorbidities were noted.
Results: A total of 113 consecutive patients were enrolled in the study, 41 in the endarterec-
tomy group and 72 in the endovascular group. The baseline levels of the studied biomarkers
did not show any statistically significant difference between the groups with the exception of
MMP-9, which showed higher concentrations in the endovascular group (median 731 vs. 401,
P ¼ 0.0007), while 24 hr after surgery the endarterectomy group featured significantly higher pe-
ripheral blood concentrations of MMP-9, S100b, and D-dimer. Conversely, no significant differ-
ence was detected in the endovascular group except the D-dimer level.
Conclusions: Neural damage biomarkers demonstrated a substantial difference between open
and endovascular carotid surgery, which, if performed in selected patients, may become a less
invasive alternative to CEA.INTRODUCTION
Stroke is one of the leading causes of death and per-
manent disability in high-income countries.1 Signif-
icant carotid artery stenosis may be a predisposing
factor in stroke, so surgical treatment can reducean open access article under the CC BY-NC-ND license
commons.org/licenses/by-nc-nd/3.0/).
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risk of death and stroke, with, on the other hand, a
higher risk of acute myocardial infarction (AMI)
and cranial nerve injury, making percutaneous
transluminal angioplasty and CAS second-line
treatment options for carotid artery stenosis. How-
ever, no long-term differences concerning the
outcome of stroke or death were demonstrated in
the meta-analysis by Meier et al.5
This meta-analysis and several trials, Carotid
Revascularization Endarterectomy versus Stenting
Trial (CREST),6,7 Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS),8 and
Steant-Protected Angioplasty versus Carotid Endar-
terectomy (SPACE),9 have shifted the balance in
favor of CEA,10 because of the lower incidence of ce-
rebrovascular complications,11 reserving endovas-
cular techniques to selected cases.
The diagnosis of periprocedural stroke relies
on clinical parameters and neuroimaging tech-
niques,12 as with all other forms of acute stroke.
Similarly to what has been done for early triage
and evaluation of cardiac symptoms compatible
with AMI, various panels of biomarkers of neural
damage13e15 have been developed and validated
in recent years. The necessity of adopting a multiple
markers approach is based on the absence of a single
molecule capable of identifying brain damage in all
its forms. S100b,16 a calcium-binding protein, is
released from astrocytesda cellular population
that is vital to neuronal trophic support being
involved inmost repair and apoptosis processes.Ma-
trix metalloproteinase-9 (MMP-9),17,18 a gelatinase,
is less neuron specific as it is a marker of inflamma-
tion, present in both active and inactive forms, the
former being more abundant within the bloode
brain barrier indicating, at high concentration, dam-
age at this level. D-dimer19 is the end product of fibri-
nolytic process. These 3 markers are part of the
triage stroke panel,13 the brain natriuretic peptide,
present in the original version, was excluded from
the perioperative assays as it could be biased by
surgery-related variables not correlated to neural
damage, such as fluid therapy and cardiac function.
A biomarker-based approach can be proposed to
assess potential periprocedural neurological damage
whose effects are still present at 24 hr; this could
help to identify more subtle variations and uncover
subclinical, active injuries that might contribute to
the development of long-term effects. In fact, an
acute elevation of these biomarkers could result
solely from minor surgical alterations to cerebral
perfusion and inflammation, while a lasting eleva-
tion at 24 hr may be correlated to a more substantial
lesion.The main objective of this investigation was to
assess the potential neural damage following open
versus endovascular carotid surgerymeasured by pe-
ripheral blood concentrationof 3 biomarkers (S100b,
MMP-9, D-dimer) at baseline and 24 hr after surgery.
METHODS
Data for this prospective pilot investigation were ob-
tained from the Carotid Markers (CARMA) study
(January 2010e2011), which sought to measure
the levels of specific biomarkers of neuronal damage
and thrombosis on candidates to CEA or CAS pre-
senting at the Department of Vascular Surgery of
the Nuovo Ospedale S. Agostino Estense (Baggio-
vara, Modena, Italy) at baseline and at 24 hr after
surgery. Approval from Institutional Ethics Com-
mittee of Modena was obtained before study initia-
tion. Patients were included in the analysis if CEA or
CAS were performed according to the below
described techniques. Written formal consent was
obtained from the study participants or legal desig-
nate. Demographic, clinical, laboratory, and radio-
graphic data were collected by a standardized
protocol. The American Society of Anesthesiologists
(ASA) physical status classification system was
adopted as a measure of the overall physical health
of the patient before surgery.
Initial assessment of the patient was performed
by echo-color duplex scan and angio-computed to-
mography (CT) of the neck and brain to define the
anatomical characteristics of the aortic arch, supra-
aortic vessels, and intracranial circulation. Asymp-
tomatic patients with stenosis >80% and/or
ulcerated lesions >50% and symptomatic patients
with stenosis >60% and/or ulcerated lesions
>50% were considered for treatment. Patients
over 65 years of age were primarily considered for
CAS at this center when favorable anatomies were
documented at angio-CT studies. Suitable anatomic
criteria for CAS included bovine and normal arches
(type I, II, and III) and adequate femoral artery ac-
cess. Endovascular treatment was withhold in cases
of stenosis of the brachiocephalic artery or at the
origin of the left common carotid artery (CCA) and
calcification of the aortic arch. Patients were consid-
ered for CAS when unsuitable for traditional sur-
gery because of clinically significant cardiac
disease, severe pulmonary disease, contralateral
laryngeal nerve palsy, restenosis >80% after CEA,
previous neck radiation exposure or radical neck
surgery, and high carotid bifurcation or intracranial
extension of a carotid lesion. Finally, CAS was per-
formed in patients at high risk of cerebral ischemia
during carotid clamping (i.e., occlusion of the
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anomalies of the circle of Willis). There is no
maximum age threshold at this center, but patients
aged under 65 years, who were suitable for surgery,
were preferably treated with CEA.
All new neurological deficits, defined as previ-
ously not documented focal or general neurological
signs or symptoms presented by the patient during
and after surgery were recorded by a consultant
neurologist.Surgical TechniquesCarotid endarterectomy. The eversion CEA tech-
niquewas performed through anoblique transection
of the ICA from the CCA, endarterectomy by ever-
sion of the ICA, endarterectomy of the carotid bifur-
cation and of the external carotid artery (ECA), and
reimplantation of the ICAon theCCA. Conventional
CEA was performed through a longitudinal arterio-
tomy from the CCA bifurcation to the ICA on the
anterior surface of the artery. Endarterectomy was
carried out after careful identification of the cleavage
plane. Arteriotomy was routinely closed with a
prosthetic patch (Finesse Fine, Maquet, NJ).
The procedure was performed during conscious
sedation: after the cannulation of a peripheral vein
with a large bore catheter and radial artery with a
20G catheter for invasive monitoring of blood pres-
sure, general anesthesia was induced using propofol
1% (1e1.5 mg/kg) and remifentanil continuous
infusion at a rate of 0.1e0.15 mg/kg/min. All patients
received succinylcholine 1 mg/kg before laryngos-
copy and topical lidocaine 4% on the vocal cords
before intubation. After the endotracheal tube was
positioned, mechanical ventilation started. The su-
perficial cervical plexus block was performed using
ropivacaine 0.75% (0.8e1.2 mg/kg). Under remi-
fentanil continuous infusion at a rate of 0.1 mg/kg/
min, the patient regained consciousness with the
ability to tolerate orotracheal intubation and me-
chanically assisted ventilation; no other anesthetic
agent was administered alongside remifentanil. Ce-
rebral blood flow adequacy, after carotid clamping,
was measured by monitoring the ability of the pa-
tient to execute simple orders (squeeze test) issued
by the anesthesiologist at regular intervals, of at least
5min ormore frequently if necessary,with the hem-
isoma contralateral to the surgical site: inability to
perform this task, in the absence of other possible
causes such as systemic hypotension,was the indica-
tion for carotid shunt placement.
The remifentanil infusion was gradually reduced
and completely discontinued at the end of the pro-
cedure and the patient was extubated.The anesthesia protocol used combines a
regional technique with conscious sedation to
ensure adequate pain control and safe airway
management.Carotid artery stenting. An access was obtained by
percutaneous puncture of the common femoral ar-
tery under local anesthesia with mepivacaine
5 mg/kg. The Piton GC carotid guide catheter
(Medtronic Invatec, Frauenfeld, Switzerland) and
Mo.Ma,20,21 a proximal cerebral embolic protec-
tion device, (Medtronic Invatec) were used in all
cases. Predilation was selectively performed with a
noncompliant coronary balloon (2.5e3.5 mm in
diameter) in case of preocclusive calcified stenosis
(a stenosis of at least 90%) which impeded stent
deployment. Self-expanding nitinol stents were
used in the study. The diameter of the stent was cho-
sen according to a 1e2 mm oversizing with a length
of 30 or 40 mm. In the case of lesions longer than
40 mm, 2 stents were inserted, with an overlapping
of 2e5 mm. Double stenting was employed for
longer lesions and not for stent design reinforce-
ment (in 1 case double stenting was employed to
avoid plaque prolapse). Stents used in this study
include X-act (Abbott Vascular, Redwood City,
CA), ViVEXX (C. R. Bard, Murray Hill, NJ), Vascu-
Flex (B. Braun Medical, Boulogne Cedex, France),
and Cristallo Ideale Carotid Stent System (Med-
tronic Invatec). Postdilation was performed with a
5  20 mm noncompliant balloon (range 4e
5.5 mm) at 8 atm, with inflation and deflation per-
formed slowly (1 atm/2 sec). After the final aspira-
tion, when there were no signs of clamping
intolerance, endovascular flushing to the ECA was
performed. Before the removal of the protection de-
vice, the postdilation balloon was reintroduced into
the ICA and reinflating at a low pressure (4 atm) to
further remodel the debris or detached protruding
plaque. The balloons in the ECA and CCA were
then deflated, allowing passage of the reinstated
hematic current into the ECA for 5e10 sec (cerebral
flow is blocked by the inflated postdilation balloon).
Then balloons were reinflated and the postdilation
balloon was deflated and removed. A second aspira-
tion was performed, checking for the absence of
debris before reinstating blood flow and removing
the device. This procedure was intended to mobilize
the unstable protruding plaque while the cerebral
flow was still blocked and redirect it into the ECA,
achieving a spreading effect of any protruding pla-
que. An intra- and extracranial angiography post
intervention was performed to assess stent patency
and eventual residual stenosis (20% is accepted)
1674 Giuliani et al. Annals of Vascular Surgeryand to visualize and assess any potential intracranial
embolization.
The choice of the stent used was based on both
anatomical and plaque-related criteria: closed cells
were preferred in linear vessels with soft plaques,
open cells in cases of tortuous anatomies with calci-
fied plaques, while hybrid cells were used in soft
plaques.Postoperative Medical TherapyAll candidates to CAS received aspirin 100 mg and
clopidogrel 75 mg daily for the 3 days preceding
the operation. During both procedures a standard
dose of heparin was administered and from the first
postoperative day an antiplatelet regimen with
aspirin 100 mg, associated for 30 days to clopidogrel
in case of CAS. Statins were added as plaque stabi-
lizers, when not absolutely contraindicated.ImmunoassaysBlood samples were obtained at admission to the
Department of Vascular Surgery and after 24 hr by
either venous puncture or a catheter placed in
the radial artery for the invasive monitoring of
blood pressure. Plasma samples were collected in
ethylenediaminetetraacetic acid tubes for D-dimer;
serum samples were collected for S100b and
MMP-9 detection. Blood samples were centrifuged
at 1,500  g within 60 min from collection. Each
serum or plasma samplewas subdivided into 2 Cryo-
Vials and stored at 80C.
SerumMMP-9 was quantified by a commercially
availableMMP-9 (human) ELISA kit (DRGDiagnos-
tics, DRG Instruments GmbH, Marburg, Germany).
Serum S100b was quantified with appropriate fully
automated electrochemiluminescence immuno-
assay (Cobas; Roche Diagnostics GmbH,Mannheim,
Germany) in accordance with the manufacturer’s
instructions. Plasma D-dimer concentration was
measured using a fully automated Tina-quant
D-dimer D-DI2 test (Cobas; Roche Diagnostics
GmbH) according to the manufacturer’s instruc-
tions. The lower limit of sensitivity of the MMP-9
assay was 0.05 ng/mL, while the analytic range for
D-dimer and S100b was 150e9,000 ng/mL and
0.005e39 mg/L, respectively.Follow-upAll included patients were scheduled for follow-up 1
week after the procedure, 1 and 6 months after-
wards: on these occasions a carotid ultrasound
scan was acquired by a vascular surgeon, who also
evaluated potential surgical complications, while a
neurologist performed a detailed neurologicalexamination to detect potential lesions correlated
to surgery and follow their evolution.Statistical AnalysisStatistical analysis was performed using Stata 10.0
(StataCorp, College Station, TX). Descriptive statis-
tics, including median and interquartile range,
were obtained for demographic variables, Wil-
coxon rank-sum test was used to compare the dis-
tributions of continuous variables, the Wilcoxon
sign-rank test for paired data, and c2 test for cate-
gorical variables. The Spearman’s rank correlation
test was used to assess the relationship between 2
interval variables.RESULTS
A total of 113 consecutive patients were enrolled in
the CARMA study, 41 in the endarterectomy group
and 72 in the endovascular group. Figure 1 reports
the enrollment flowchart: 82.9% of the subjects in
the endarterectomy group were treated with patch
angioplasty and 17.1% with eversion.
The demographics for the study population did
not show statistically significant differences be-
tween groups as regard to sex, vascular risk factors,
and relevant past medical history, with the excep-
tion of age and peripheral artery disease (PAD)
(Table I); the median degree of preoperative carotid
stenosis, measured by echo-color duplex scan as
percentage of lumen reduction in the vessel to be
operated, was 75% in both groups (P ¼ 0.1961).
No deaths were reported during hospital stay and
2 patients died during the follow-up period
(1.6%): one for the complications of a stroke at
day 24 in the endovascular group and one after a ce-
rebral hemorrhage at day 150 in the endarterectomy
group.
The mean duration of the perioperative period of
the endarterectomy groupwas 95.8 ± 9.0min, while
for CAS it lasted on average 52.7 ± 17.6 min
(P < 0.0001). There were 1 ASA 1, 25 ASA 2, and
15 ASA 3 patients in the endarterectomy group
compared with 25 ASA 2, 45 ASA 3, and 2 ASA 4
patients in the endovascular group; the anesthesio-
logic and surgical characteristic of the studied
cohort presented statistically significant differences
of ASA classification and duration of carotid flow
arrest, while the proportion of episodes of new
neurological deficits during surgery measured as
inability to perform squeeze test did not reach the
level of significance (Table II). One stroke was re-
ported during postoperative period in each group
with documented ischemic lesions at brain imaging
Fig. 1. Enrollment flowchart.
Table I. Patient demographics for





(n ¼ 72) P value
Age (years) 71.0 ± 1.3 75.5 ± 0.9 0.0047
Sex (male) 70.7% 59.7% 0.242
Tobacco smoke 24.4% 18.1% 0.421
Dyslipidemia 56.1% 43.1% 0.182
Diabetes 17.1% 27.8% 0.199
Hypertension 70.7% 81.9% 0.167
AMI 14.6% 25.0% 0.195
TIA 19.5% 16.7% 0.703
Stroke 34.1% 20.8% 0.119
PAD 14.6% 36.1% 0.015
TIA, transitory ischemic attack.
Age is expressed as mean ± standard deviation; for the
categorical variables, percentages are given as a proportion of
the patients who had the characteristics.





(n ¼ 72) P value
ASA 2 (2e3) 3 (2e3) 0.0038




ASA and clamp are expressed as median and interquartile range;
for the categorical variables, percentages are given as a
proportion of the patients who had the characteristics. There
were 1 ASA 1, 25 ASA 2, and 15 ASA 3 patients in the
endarterectomy group compared with 25 ASA 2, 45 ASA 3,
and 2 ASA 4 patients in the endovascular group. Seven of the
9 patients who failed to perform the squeeze test in the
endarterectomy group were used a shunt to partially restore
carotid blood flow. The differences of the distributions of the
continuous variables were assessed by the Wilcoxon’s rank-
sum test, while for the categorical variables c2 test was used.
Clamp, duration of carotid flow arrest; squeeze test failure,
percentage of patients who failed the squeeze test.
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hemisoma.
Table III summarizes the complications related to
surgery identified during the follow-up; no statisti-
cally significant differences of prevalence were pre-
sent between the 2 groups.
The baseline levels of the studied biomarkers did
not show any statistically significant difference be-
tween groups with the exception of MMP-9, which
showed higher concentrations in the endovascular
group (median 731 vs. 401, P ¼ 0.0007). Postopera-
tive levels of MMP-9, S100b, and D-dimer weresignificantly higher in the endarterectomy group.
D-dimer was the only marker to be higher after sur-
gery in the endovascular group. This profile is
compatible with a profile of increased inflammation
and astrocyte damage in the endarterectomy group
(Fig. 2).
A Wilcoxon rank-sum test was performed to
assess the differences in concentration of the studied
biomarkers in the individuals who failed the
Table III. Main complications reported during the follow-up period for each group (no statistically
significant difference in the prevalence of complications was present between groups)
Groups
Follow-up
1 week (no. of cases) 1 month (no. of cases) 6 months (no. of cases)
Endovascular
(n ¼ 72)
Reduction of muscle power of the
contralateral upper limb (1)




Death because of sepsis (1)
Endarterectomy
(n ¼ 41)
Hypoglossal nerve involvement (2)
Upper limb palsy with thrombosis
of the operated vessel (1)a
Ischemic stroke (1)a Death because of cerebral
hemorrhage (1)
aSame patient.
1676 Giuliani et al. Annals of Vascular Surgerysqueeze test within each group: there was a statisti-
cally significant difference between D-dimer post-
operative levels in the endarterectomy group
(median in failure subgroup 1886 vs. 818 ng/mL,
P ¼ 0.0304). Similarly, a statistically significant dif-
ference was shown between postoperative S100b
levels in those subjects where shunt was used dur-
ing endarterectomy (0.083 mg/mL in the shunt sub-
group vs. 0.055 mg/mL, P ¼ 0.0066).
The Spearman’s rank correlation test was used to
assess the relationship between the level of the stud-
ied biomarkers at 24 hr and the duration of carotid
flow arrest: no statistically significant correlations
were observed between the concentrations of the
3 biomarkers included in this panel at 24 hr and
the duration of carotid flow arrest.DISCUSSION
Carotid surgery is one of the main vascular inter-
ventions. CEA is considered the gold standard tech-
nique for symptomatic stenosis, while CAS is
indicated only for selected cases as its generalized
application is controversial.3,4 In fact, randomized
trials have demonstrated an excess in complications
for the endovascular treatment when compared
with open surgery.10,11 Paraskevas et al.22 in the
critics to the CREST study have shown a substantial
superiority of CEA versus CAS, but in their conclu-
sions they emphasized that CREST used outdated
technology and indications. Under this perspective,
this study investigates the effects of the implementa-
tion of new technical solutions to CAS from a bio-
marker’s point of view.
However, the CAS is characterized by shorter
duration of the procedure and the potential for
reduced invasivity. Factors that may influence the
outcome of CAS are the experience of the operator
and the anatomical and clinical characteristics ofthe patient, which make them suitable for an endo-
vascular approach: randomizationmay be especially
challenging because standard evaluation methods
(angiography and echocolordoppler) could fail to
identify conditions that contraindicate CEA or
CAS. Epiaortic vessels angio-CT with analysis of
the Willis circle, carotid plaque composition are
often necessary to identify patient suitable for
CAS. The adoption of specific devices (guide cathe-
ters and cerebral protection devices) makes CAS a
feasible approach also in patients over 65 years of
age, reducing some of the most common complica-
tions23e25 CAS still remains a technique for selected
cases26 but a careful preoperative assessment can
extend its application to larger portion of patients,
who may benefit from the reduced invasivity and
duration of an endovascular approach when
compared with open surgery.
The rate of reported complications seems compa-
rable between groups, especially when considering
the endovascular procedures.11
Mantese et al.6 showed that age was the only
parameter affecting treatment efficacy in CAS
versus CEA for carotid surgery but the adoption of
additional cerebral protection devices and specific
guidewires may improve the efficacy of CAS in pa-
tients over 70 as suggested current data. In fact con-
trary to what are the actual indications to CAS, the
present endovascular group was characterized by
older age and a higher prevalence of PAD, as a less
invasive approach was preferred in higher comor-
bidity patients with suitable anatomy, as reflected
also by the ASA physical status classification assess-
ment. The shorter duration of the procedure, the
feasibility with local anesthesia, so without the
need for mechanical ventilation, were considered
beneficial factors in the perioperative management
of these individuals, as an attempt to reduce the
impact on the homeostasis of the elderly vascular
patient. In fact, in these subjects complications can
Fig. 2. Panel of biomarkers: data regarding S100b pro-
tein, matrix metalloproteinase-9, and D-dimer peripheral
blood levels, at baseline (preoperative) and 24 hr after
surgery (postoperative), are reported as median with
interquartile range for the endovascular and endarterec-
tomy groups.
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cal procedure.
The studied biomarkers showed a significant in-
crease from baseline in the open surgery group,
even if this was, apparently, not related to theduration of carotid flow arrest. D-dimer, which re-
flects the activation of the coagulation cascade,
raised in both groups likely as a consequence of ca-
rotid atherosclerosis and activation of the fibrino-
lytic cascade27 during and after surgery.
The correlation between the serum/plasma con-
centrations of a panel of specific biomarkers with
neural damage has already been demonstrated.
Here, we propose that their application to vascular
surgery, especially to carotid interventions, can
contribute to detect subclinical lesions that may
not have direct consequences in the short term but
can manifest as neurological status deterioration
on a longer term. Postoperative cognitive impair-
ment is associated to carotid surgery because of
possible emboli that may detach from the carotid
plaque during the procedure and the underlying
clinical condition of the patient that may predispose
him to the development of cerebrovascular
pathologies.
S100b peripheral levels, although characterized
by a half-life of 25 min, have shown a good correla-
tion with cerebral lesions 24 hr after cardiac sur-
gery28; elevated levels of this protein have been
described after CEA probably as consequence of
transitory episodes of cerebral hypoperfusion29
and carotid clamping.30 Contrary to what reported
by Brightwell et al.,29 our data show that the treat-
ment modality affected S100b peripheral levels
24 hr after the operation only in the CEA group.
These findings were not related to the length of
the carotid flow arrest, so they may be dependent
on a more effective proximal cerebral protection
strategy, which, however, calls for further
assessment.
MMP-9, a gelatinase, peaks during CEA in corre-
lation to vessel occlusion31: it is a marker of inflam-
mation and damage of the bloodebrain barrier
therefore its postoperative increase could be related
to microembolization and/or transient brain tissue
damage. Other conditions may influence the con-
centration of MMP-9, such as chronic inflammatory
diseases, tumors, and venous diseases, but the study
compared a preoperative concentration with a post-
operative level and it is unlikely that these con-
founding conditions are manifested in the 48-hr
interval between samples collection.
MMP-9 adds value to the panel of markers as it
explores the inflammation and alteration of the
bloodebrain barrier that is likely affected during
surgery.
Interestingly, in this study, the levels of MMP-9
were significantly higher in the CAS group. This
suggests a higher ‘‘baseline’’ inflammatory state or
silent areas of damage associated with subclinical
1678 Giuliani et al. Annals of Vascular Surgerybloodebrain barrier dysfunction in this group of pa-
tients. Nevertheless, the incidence of neurological
deficits did not differ in the 2 groups both during
surgery and the 6-month follow-up.
The present data show that the endovascular
approach determined a minor release of neural
damage biomarkers than traditional open surgery
for factors independent from carotid flow arrest
duration but probably related to intrinsic character-
istics of the procedure somehow entailing an
improved cerebral protection, as shown byMontorsi
et al.21 with a reduced rate of microembolization
associated with the use of a proximal protection de-
vice. However, the statistically shorter duration of
carotid flow arrest experienced during the endovas-
cular procedures may have presumably led to a
reduced neural damage, as highlighted by the bio-
markers’ trend.
The detection of intraprocedural microembolic
events with transcranial Doppler could be correlated
to the peripheral concentration of the studied
biomarkers to provide further validation of this
approach.LimitationsThe relatively small group of patients studied,
enrolled in a single center, may limit the extent of
the conclusions. Randomization was not imple-
mented because of the substantially different sur-
gical characteristics peculiar to patients suitable
for endovascular surgery, which would bias the
outcome of the procedures. Even if randomization
would have been the best option in statistical
terms, the highly individualized diagnostic work-
up tailored on the clinical profile of the patients
made it incompatible with an investigation on
biomarkers.
The panel of markers could have comprised other
neuron-specific markers and integrated their levels
with imaging data to improve the diagnostic
accuracy.CONCLUSIONS
Peripheral neural damage biomarkers, an auxiliary
diagnostic tool in the detection of subclinical lesions,
demonstrated a substantial difference between open
and endovascular carotid surgery, which, if per-
formed in selected patients, may become a less inva-
sive alternative to CEA. Data from this study do not
support previous literature results obtained in ran-
domized trials showing an excess in complications
for the endovascular treatment when compared
with open surgery. These findings would call forfurther investigation to better assess the relationship
between open and endovascular surgery and clinical
neural damage, both in the acute phase and during
follow-up.
REFERENCES
1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life
years (DALYs) for 291 diseases and injuries in 21 regions,
1990-2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 2012;380:2197e223.
2. Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of
recurrent ischemic stroke. Am Fam Physician 2007;76:
382e8.
3. Erickson KM, Cole DJ. Carotid artery disease: stenting vs
endarterectomy. Br J Anaesth 2010;105(Suppl 1):i34e9.
4. Skerritt MR, Block RC, Pearson TA, et al. Carotid endarter-
ectomy and carotid artery stenting utilization trends over
time. BMC Neurol 2012;12:7.
5. Meier P, Knapp G, Tamhane U, et al. Short term and inter-
mediate term comparison of endarterectomy versus stenting
for carotid artery stenosis: systematic review and meta-
analysis of randomised controlled clinical trials. BMJ
2010;340:c467.
6. Mantese VA, Timaran CH, Chiu D, et al. The Carotid Revas-
cularization Endarterectomy versus Stenting Trial (CREST):
stenting versus carotid endarterectomy for carotid disease.
Stroke 2010;41(10 Suppl):S31e4.
7. Hill MD, Brooks W, Mackey A, et al. Stroke after carotid
stenting and endarterectomy in the Carotid Revasculariza-
tion Endarterectomy versus Stenting Trial (CREST). Circula-
tion 2012;126:3054e61.
8. Bonati LH, Ederle J, McCabe DJ, et al. Long-term risk of ca-
rotid restenosis in patients randomly assigned to endovascu-
lar treatment or endarterectomy in the Carotid and
Vertebral Artery Transluminal Angioplasty Study (CAVA-
TAS): long-term follow-up of a randomised trial. Lancet
Neurol 2009;8:908e17.
9. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the
Stent-Protected Angioplasty versus Carotid Endarterectomy
(SPACE) study to treat symptomatic stenoses at 2 years: a
multinational, prospective, randomised trial. Lancet Neurol
2008;7:893e902.
10. International Carotid Stenting Study investigators, Ederle J,
Dobson J, et al. Carotid artery stenting compared with end-
arterectomy in patients with symptomatic carotid stenosis
(International Carotid Stenting Study): an interim analysis
of a randomised controlled trial. Lancet 2010;375:985e97.
11. Bonati LH, Lyrer P, Ederle J, et al. Percutaneous translumi-
nal balloon angioplasty and stenting for carotid artery steno-
sis. Cochrane Database Syst Rev 2012;(9):CD000515.
12. Perry JM, McCabe KK. Recognition and initial management
of acute ischemic stroke. Emerg Med Clin North Am
2012;30:637e57.
13. Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness
of a biomarker-based diagnostic test for acute stroke: the
Biomarker Rapid Assessment in Ischemic Injury (BRAIN)
study. Stroke 2009;40:77e85.
14. Sibon I, Rouanet F, Meissner W, et al. Use of the Triage
Stroke Panel in a neurologic emergency service. Am J Emerg
Med 2009;27:558e62.
15. Ahmad O, Wardlaw J, Whiteley WN. Correlation of levels of
neuronal and glial markers with radiological measures of
infarct volume in ischaemic stroke: a systematic review. Cer-
ebrovasc Dis 2012;33:47e54.
Vol. 28, No. 7, October 2014 Neural damage during carotid surgery 167916. Cata JP, Abdelmalak B, Farag E. Neurological biomarkers in
the perioperative period. Br J Anaesth 2011;107:844e58.
17. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix
metalloproteinase-9 as a marker for acute ischemic stroke:
a systematic review. J Stroke Cerebrovasc Dis 2011;20:
47e54.
18. Graham CA, Chan RW, Chan DY, et al. Matrix metallopro-
teinase 9 mRNA: an early prognostic marker for patients
with acute stroke. Clin Biochem 2012;45:352e5.
19. Hasan N, McColgan P, Bentley P, et al. Towards the identi-
fication of blood biomarkers for acute stroke in humans: a
comprehensive systematic review. Br J Clin Pharmacol
2012;74:230e40.
20. Diederich KW, Scheinert D, Schmidt A, et al. First clinical
experiences with an endovascular clamping system for neu-
roprotection during carotid stenting. Eur J Vasc Endovasc
Surg 2004;28:629e33.
21. Montorsi P, Caputi L, Galli S, et al. Microembolization
during carotid artery stenting in patients with high-risk,
lipid-rich plaque. A randomized trial of proximal versus
distal cerebral protection. J Am Coll Cardiol 2011;58:
1656e63.
22. Paraskevas KI, Mikhailidis DP, Liapis CD, et al. Critique of
the Carotid Revascularization Endarterectomy versus Stent-
ing Trial (CREST): flaws in CREST and its interpretation. Eur
J Vasc Endovasc Surg 2013;45:539e45.
23. Moratto R, Veronesi J, Silingardi R, et al. How to simplify
the approach to the supra-aortic trunks. J Cardiovasc Surg
(Torino) 2013;54:23e31.24. Moratto R, Veronesi J, Silingardi R, et al. Urgent carotid ar-
tery stenting with technical modifications for patients with
transient ischemic attacks and minor stroke. J Endovasc
Ther 2012;19:627e35.
25. Coppi G, Moratto R, Veronesi J, et al. Carotid artery stent
fracture identification and clinical relevance. J Vasc Surg
2010;51:1397e405.
26. Gahremanpour A, Perin EC, Silva G. Carotid artery stenting
versus endarterectomy: a systematic review. Tex Heart Inst J
2012;39:474e87.
27. Georgiadis D, Berger A, Kowatschev E, et al. Predictive
value of S-100beta and neuron-specific enolase serum levels
for adverse neurologic outcome after cardiac surgery. J
Thorac Cardiovasc Surg 2000;119:138e47.
28. Krupinski J, Catena E, Miguel M, et al. D-dimer local
expression is increased in symptomatic patients undergoing
carotid endarterectomy. Int J Cardiol 2007;116:174e9.
29. Brightwell RE, Sherwood RA, Athanasiou T, et al. The
neurological morbidity of carotid revascularisation: using
markers of cellular brain injury to compare CEA and CAS.
Eur J Vasc Endovasc Surg 2007;34:552e60.
30. Falkensammer J, Oldenburg WA, Hendrzak AJ, et al. Evalu-
ation of subclinical cerebral injury and neuropsychologic
function in patients undergoing carotid endarterectomy.
Ann Vasc Surg 2008;22:497e504.
31. Bicknell CD, Peck D, Alkhamesi NA, et al. Relationship of
matrix metalloproteinases and macrophages to embolization
during endoluminal carotid interventions. J Endovasc Ther
2004;11:483e93.
